Repligen (RGEN) 10-Q 8 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	RGEN
Entity Registrant Name	REPLIGEN CORP
Entity Central Index Key	730272
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		32,852,300

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$31,210,500	$35,363,024
Marketable securities	23,257,730	23,090,209
Accounts receivable, less reserve for doubtful accounts of $41,222 and $40,644, respectively	14,690,994	7,760,382
Other receivables	394,415	239,890
Inventories	12,235,719	12,383,633
Deferred tax asset, net	4,928	4,928
Prepaid expenses and other current assets	1,717,654	2,103,576
Total current assets	83,511,940	80,945,642
Property, plant and equipment, at cost:
Leasehold improvements	13,230,820	9,108,214
Equipment	12,983,947	13,115,630
Furniture and fixtures	2,551,446	2,270,347
Construction in progress	45,056	3,847,746
Total property, plant and equipment, at cost	28,811,269	28,341,937
Less: Accumulated depreciation	-14,201,629	-13,815,697
Property, plant and equipment, net	14,609,640	14,526,240
Long-term marketable securities	1,814,358	3,550,210
Intangible assets, net	13,883,208	14,636,307
Goodwill	14,314,822	14,184,835
Restricted cash	450,271	450,000
Total assets	128,584,239	128,293,234
Current liabilities:
Accounts payable	4,131,614	3,863,350
Accrued liabilities	9,052,444	6,819,063
Total current liabilities	13,184,058	10,682,413
Other long-term liabilities	3,468,166	5,879,013
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $.01 par value, 5,000,000 shares authorized, no shares issued or outstanding
Common stock, $.01 par value, 80,000,000 shares authorized, 32,851,500 shares at March 31, 2015 and 32,774,374 shares at December 31, 2014 issued and outstanding	328,515	327,744
Additional paid-in capital	199,200,343	198,064,414
Accumulated other comprehensive income (loss)	-9,639,120	-5,773,142
Accumulated deficit	-77,957,723	-80,887,208
Total stockholders' equity	111,932,015	111,731,808
Total liabilities and stockholders' equity	$128,584,239	$128,293,234

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accounts receivable, reserve for doubtful accounts	$41,222	$40,644
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	32,851,500	32,774,374
Common stock, shares outstanding	32,851,500	32,774,374

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue:
Product revenue	$20,816,276	$14,334,687
Royalty and other revenue		1,991,166
Total revenue	20,816,276	16,325,853
Operating expenses:
Cost of product revenue	8,072,904	6,335,064
Cost of royalty revenue	0	0
Research and development	1,567,574	1,200,990
Selling, general and administrative	6,024,526	3,383,610
Contingent consideration - fair value adjustments	1,112,374	98,320
Total operating expenses	16,777,378	11,017,984
Income from operations	4,038,898	5,307,869
Investment income	36,585	101,816
Interest expense	-9,041	-14,085
Other income	132,031	2,505
Income before income taxes	4,198,473	5,398,105
Income tax provision	1,268,986	1,121,002
Net income	2,929,487	4,277,103
Earnings per share:
Basic	$0.09	$0.13
Diluted	$0.09	$0.13
Weighted average shares outstanding:
Basic	32,754,862	31,962,843
Diluted	33,450,611	32,831,019
Other comprehensive income:
Unrealized gain (loss) on investments	-17,369	2,184
Foreign currency translation loss	-3,848,609	-143,153
Comprehensive income (loss)	($936,491)	$4,136,134

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$2,929,487	$4,277,103
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	1,150,520	892,407
Stock-based compensation expense	701,982	307,425
Deferred tax expense	86,552	7,566
Loss on revaluation of contingent consideration	1,112,374	98,320
Changes in assets and liabilities:
Accounts receivable	-7,237,522	-94,064
Royalties and other receivables	-154,525	6,730,818
Inventories	-513,643	331,087
Prepaid expenses and other current assets	314,212	-209,701
Accounts payable	434,892	-236,176
Accrued liabilities	1,379,713	-3,999,779
Long-term liabilities	-2,508,399	-106,216
Net cash provided by (used in) operating activities	-2,304,357	7,998,790
Cash flows from investing activities:
Purchases of marketable securities	-3,286,890	-8,970,763
Redemptions of marketable securities	4,837,850	10,529,183
Purchases of property, plant and equipment	-1,271,796	-596,788
Net cash provided by investing activities	279,164	961,632
Cash flows from financing activities:
Exercise of stock options	402,005	497,709
Payment of contingent considerations	-99,000
Net cash provided by financing activities	303,005	497,709
Effect of exchange rate changes on cash and cash equivalents	-2,430,336	-78,163
Net increase (decrease) in cash and cash equivalents	-4,152,524	9,379,968
Cash and cash equivalents, beginning of period	35,363,024	39,829,653
Cash and cash equivalents, end of period	31,210,500	49,209,621
Supplemental disclosure of non-cash investing activities:
Income taxes paid	$1,100,000	$466,000

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Basis of Presentation	1	Basis of Presentation
	The consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company,” “Repligen” or “we”) in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by U.S. GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
	In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Acquisitions_Goodwill_and_Othe

Acquisitions, Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2015
Acquisitions, Goodwill and Other Intangible Assets	2	Acquisitions, Goodwill and Other Intangible Assets
	Acquisitions
	Refine Technology, LLC
	On June 2, 2014, pursuant to the terms of the Asset Purchase Agreement, dated as of June 2, 2014 (the “Asset Purchase Agreement”), by and among the Company, Refine Technology, LLC (a limited liability company formed under the laws of the State of New Jersey) (“Refine”), the members of Refine, Jerry Shevitz, Refine Technology Sales LLC (a limited liability company formed under the laws of the State of New Jersey) and Refine Technology Sales Asia PTE. LTD. (a limited private company organized in the Republic of Singapore), the Company acquired the business of Refine, including Refine’s Alternating Tangential Flow (“ATF”) System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process (the “Refine Business” and the acquisition of the Refine Business, the “Refine Acquisition”). Pursuant to the Asset Purchase Agreement, Repligen purchased all of the assets related to Refine’s ATF system and assumed certain specified liabilities related to Refine’s ATF system. This acquisition strengthened Repligen’s bioprocessing business by adding a complementary product line while expanding its direct sales presence worldwide. The transaction was accounted for as a purchase of a business under ASC 805, Business Combinations. The terms of the acquisition included an upfront cash payment of $21,235,937 less $66,277 as a result of the final determination of working capital, issuance of 215,285 shares of the Company’s $0.01 par value common stock valued at $4,000,000, potential milestone payments totaling up to $10,900,000 for the achievement of specific sales targets in the years 2014, 2015 and 2016, and future potential payments up to $7,500,000 out of any amounts that might be received in connection with the resolution, withdrawal or settlement of certain patent disputes with a third party. During the three months ended March 31, 2015, the Company paid Refine a $1,000,000 milestone payment for achievement of the 2014 sales target under the Asset Purchase Agreement. The $10,900,000 contingent consideration had an initial probability weighted fair value at acquisition of $1,370,000. The $7,500,000 contingent consideration had only a nominal probability weighted fair value at acquisition. In addition to the initial consideration, approximately $774,000 was paid to Refine following the acquisition under a Transition Services Agreement under which certain employees of Refine provided services to the Company for up to six months in support of the Refine Business. As these payments were contingent upon future service, they were recognized ratably as operating expense while the services were provided.
	Consideration Transferred
	The Company accounted for the Refine Acquisition as the purchase of a business under U.S. GAAP. Under the acquisition method of accounting, the assets of the Refine Business were recorded as of the acquisition date, at their respective fair values, and consolidated with those of Repligen. The fair value of the net assets acquired was approximately $ 26,539,660.
	The preparation of the valuation required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates.
	The total consideration transferred follows:
	Cash consideration,		$	21,169,660
	Value of common stock issued			4,000,000
	Estimated fair value of contingent consideration			1,370,000
	Total consideration transferred		$	26,539,660
	The fair value of contingent consideration was determined based upon a probability weighted analysis of expected future payments to be made to the seller. The Company paid to Refine $1,000,000 for achievements of sales targets met in 2014, and could make payments of up to $9,900,000 if specific sales targets are met for years 2015 and 2016. In addition, the Company could pay Refine up to $7,500,000 out of any receipts that might be received in connection with the resolution, withdrawal or settlement of certain patent disputes with a third party. The liability for contingent consideration is included in current and long-term liabilities on the consolidated balance sheets and will be remeasured at each reporting period until the contingency is resolved. Please see Note 2—Fair Value Measurement for further details.
	Acquisition related costs are not included as a component of consideration transferred, but are expensed in the periods in which the costs are incurred. The Company incurred approximately $817,835 in transaction costs related to the Refine Acquisition. The transaction costs are included in selling, general and administrative expenses in the consolidated statements of comprehensive income.
	Fair Value of Net Assets Acquired
	The allocation of purchase price was based on the fair value of assets acquired and liabilities assumed as of June 2, 2014. The components and allocation of the purchase price consists of the following amounts:
	Accounts receivable		$	1,646,746
	Inventory			1,034,657
	Other current assets			184,080
	Fixed assets			84,662
	Customer relationships			6,400,000
	Developed technology			2,000,000
	In process research and development (“IPR&D”)			1,600,000
	Trademark and trade name			700,000
	Accounts payable and other liabilities assumed			(431,307	)
	Goodwill			13,320,822
	Net assets acquired		$	26,539,660
	Of the consideration paid, $6,400,000 represents the fair value of customer relationships that will be amortized over the determined useful life of 10 years and $2,000,000 represents the fair value of developed technology that will be amortized over a determined useful life of 15 years. $700,000 represents the fair value of trademark and trade name determined to have an indefinite useful life and is not subject to amortization.
	$1,600,000 of the consideration paid represents the fair value of acquired IPR&D projects that are considered identifiable assets as of the acquisition date. Those assets are considered indefinite lived until efforts associated with the projects are completed or abandoned. The major acquired technology IPR&D relates to the development of a single use system product extension to the ATF system business. The IPR&D project is not currently amortized and is reviewed for impairment at least annually. There was no evidence of impairment to IPR&D as of March 31, 2015. The excess of the purchase price over the fair value of tangible and intangible assets acquired was recorded to goodwill. The goodwill recognized is attributable to expected synergies that the Company will realize from this acquisition. This goodwill is deductible for tax purposes over the next 15 years.
	The assessment of fair value is preliminary and is based on information that was available to management at the time the condensed consolidated financial statements were prepared. The Company is finalizing its inventory valuation and, accordingly, such amounts may change.
	Revenue, Net Income and Pro Forma Presentation
	The Company recorded revenue from Refine of $6,793,000 from June 2, 2014 through December 31, 2014 and $2,582,000 for the three months ended March 31, 2015. The segregation of Refine’s net income is administratively impractical, as the Company operates as one operating segment and does not separately allocate expenses. The Company has included the operating results of Refine in its consolidated statements of operations since the June 2, 2014 acquisition date. The following table presents unaudited supplemental pro forma information as if the Refine Acquisition had occurred as of January 1, 2014.
			Three Months ended			Three Months ended
			March 31,			March 31,
			2015			2014
	Total revenue		$	20,816,000		$	18,242,000
	The unaudited pro forma information for the three months ended March 31, 2015 and 2014 was calculated after applying the Company’s accounting policies and the impact of acquisition date fair value adjustments. The pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments to reflect the pro forma results of operations as if the acquisition had occurred as of the beginning of the periods presented, such as fair value adjustments to inventory and increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities.
	Other Intangible Assets
	Intangible assets, except for the Refine Technology, LLC tradename and in-process research and development, are amortized over their useful lives using the estimated economic benefit method, as applicable, and the amortization expense is recorded within selling, general and administrative expense in the Company’s statements of comprehensive income (loss). The Refine Technology, LLC tradename and in-process research and development are not amortized. The Company reviews our indefinite-lived intangible assets not subject to amortization to determine if adverse conditions exist or a change in circumstances exists that would indicate an impairment. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for our products or changes in the size of the market for our products. An impairment results if the carrying value of the asset exceeds the estimated fair value of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its intangible assets are recoverable at March 31, 2015.
	Other intangible assets consisted of the following at March 31, 2015:
			Gross Carrying			Accumulated			Weighted
			Amount			Amortization			Average
									Useful Life
									(in years)
	Technology – developed		$	3,283,913		$	(803,409	)		12
	In process research and development			1,600,000			—			—
	Patents			240,000			(155,000	)		8
	Customer relationships			11,702,387			(2,684,683	)		9
	Trademark/ tradename			700,000			—			—
	Total other intangible assets		$	17,526,300		$	(3,643,092	)		10
	Other intangible assets consisted of the following at December 31, 2014:
			Gross Carrying			Accumulated			Weighted
			Amount			Amortization			Average
									Useful Life
									(in years)
	Technology – developed		$	3,337,658		$	(750,066	)		12
	In process research and development			1,600,000			—			—
	Patents			240,000			(147,500	)		8
	Customer relationships			12,202,219			(2,546,004	)		9
	Trademark/ tradename			700,000			—			—
	Total other intangible assets		$	18,079,877		$	(3,443,570	)		10
	Amortization expense for amortized intangible assets was approximately $401,000 for the three months ended March 31, 2015. In each of the next five years, the Company expects to record amortization expense of:
	Years Ending		Amortization Expense
	December 31, 2015 (nine months remaining)		$	1,250,000
December 31, 2016			1,715,000
December 31, 2017			1,715,000
December 31, 2018			1,551,000
December 31, 2019			1,536,000
December 31, 2020			1,208,000
Recently Issued Accounting Pronouncements
In May 2014, the FASB issued ASU No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. This guidance is effective for fiscal years beginning after December 15, 2016, with early adoption not permitted. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. On April 1, 2015, the FASB proposed deferring the effective date by one year to December 15, 2017 for annual reporting periods beginning after that date. The FASB also proposed permitting early adoption of the standard, but not before the original effective date of December 15, 2016. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its consolidated financial statements.

Revenue_Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2015
Revenue Recognition	3	Revenue Recognition
	Product Sales
	The Company’s revenue recognition policy is to recognize revenues from product sales and services in accordance with ASC 605, Revenue Recognition. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Determination of whether these criteria have been met are based on management’s judgments primarily regarding the fixed nature of the fee charged for the product delivered and the collectability of those fees. The Company has a few longstanding customers who comprise the majority of revenue and have excellent payment histories and therefore the Company does not require collateral. The Company has had no significant write-offs of uncollectible invoices in the periods presented. When more than one element such as equipment, consumables, and services are contained in a single arrangement, the Company allocates revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or management’s best estimate of selling price.
	The Company’s product revenues are from the sale of bioprocessing products, equipment devices, and related consumables used with these equipment devices to customers in the life science and biopharmaceutical industries. On product sales to end customers, revenue is recognized, net of discounts, when both the title and risk of loss have transferred to the customer, as determined by the shipping terms provided there are no uncertainties regarding acceptance, and all obligations have been completed. Generally, our product arrangements for equipment sales are multiple element arrangements, and may include services, such as installation and training, and multiple products, such as consumables and spare parts. In accordance with ASC 605-25, based on terms and conditions of the product arrangements, the Company believes that these services and undelivered products can be accounted for separately from the delivered product element as the delivered products have value to our customers on a standalone basis. Accordingly, revenue for services not yet performed at the time of product shipment are deferred and recognized as such services are performed. The relative selling price of any undelivered products is also deferred at the time of shipment and recognized as revenue when these products are delivered. For product sales to distributors, the Company recognizes revenue for both equipment and consumables upon delivery to the distributor unless direct shipment to the end user is requested. In this case, revenue is recognized upon delivery to the end user’s location. In general, distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Sales to distributors are not contingent upon resale of the product.
	At the time of sale, the Company also evaluates the need to accrue for warranty and sales returns. The supply agreements the Company has with its customers and the related purchase orders identify the terms and conditions of each sale and the price of the goods ordered. Due to the nature of the sales arrangements, inventory produced for sale is tested for quality specifications prior to shipment. Since the product is manufactured to order and in compliance with required specifications prior to shipment, the likelihood of sales return, warranty or other issues is largely diminished. Furthermore, there is no customer right of return in our sales agreements. Sales returns and warranty issues are infrequent and have had nominal impact on the Company’s financial statements historically.
	Sale of Intellectual Property to BioMarin
	In January 2014, the Company entered into an asset purchase agreement (the “BioMarin Asset Purchase Agreement”) with BioMarin Pharmaceutical Inc. (“BioMarin”) to sell Repligen’s histone deacetylase inhibitor (HDACi) portfolio. Pursuant to the terms of the BioMarin Asset Purchase Agreement, the Company received $2 million from BioMarin as an upfront payment on January 30, 2014 and a $125,675 payment on September 3, 2014 upon completion of the Technology Transfer. The Company is entitled to receive up to $160 million in potential future milestone payments for the development, regulatory approval and commercial sale of portfolio compounds included in the agreement. These potential milestone payments are approximately 37% related to clinical development and 63% related to initial commercial sales in specific geographies. In addition, Repligen is eligible to receive royalties on sales of therapeutic products originating from the HDACi portfolio. The royalty rates are tiered and begin in the mid-single-digits for the first HDACi portfolio product and for the first non-HDACi portfolio product with lesser amounts for any backup products developed under the BioMarin Asset Purchase Agreement. Repligen’s receipt of these royalties is subject to customary offsets and deductions. There are no refund provisions in this agreement. The Company recognized $0 and $2.1 million of revenue in the three months ended March 31, 2015 and in the fiscal year ended December 31, 2014, respectively, related to the transfer of the HDACi technology under the BioMarin Asset Purchase Agreement. Any milestones earned upon specified clinical development or commercial sales events or future royalty payments, under the BioMarin Asset Purchase Agreement will be recognized as revenue when they are earned.
	Activities under this agreement were evaluated in accordance with ASC 605-25 to determine if they represented a multiple element revenue arrangement. The Company identified the following deliverables in the BioMarin agreement:
		•	The assignment by Repligen to BioMarin of the Repligen Technology (“Repligen Know-How” and “Repligen Patents”) and the Scripps Agreement (the “Transferred Assets”);
		•	The transfer of certain notebooks, data, documents, biological materials (if any) and other such documents in our possession that might be useful to further development of the program (the “Technology Transfer”).
	Two criteria must be met in order for a deliverable to be considered a separate unit of accounting. The first criterion requires that the delivered item or items have value to the customer on a stand-alone basis. The second criterion, which relates to evaluating a general right of return, is not applicable because such a provision does not exist in the BioMarin Asset Purchase Agreement. The deliverables outlined above were deemed to have stand-alone value and to meet the criteria to be accounted for as separate units of accounting. Factors considered in this determination included, among other things, BioMarin’s right under the agreement to assign the Transferred Assets, whether any other vendors sell the items separately and if BioMarin could use the delivered item for its intended purpose without the receipt of the remaining deliverables. If multiple deliverables included in an arrangement are separable into different units of accounting, the multiple-element arrangements guidance addresses how to allocate the arrangement consideration to those units of accounting. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative selling price.
	The Company identified the arrangement consideration to allocate among the units of accounting as the $2.0 million non-refundable up-front payment and the $125,675 payment to be received upon completion of the Technology Transfer. The Company excluded the potential milestone payments provided for in the BioMarin Asset Purchase Agreement from the arrangement consideration as they were not considered fixed or determinable at the time the BioMarin Asset Purchase Agreement was signed. Because Repligen had not sold these items on a standalone basis previously, Repligen had no vendor-specific objective evidence of selling price. Furthermore, Repligen did not have detailed third-party evidence of selling price, and as a result we used our best estimate of selling price for each item. In determining these prices, Repligen considered what Repligen would be willing to sell the items for on a standalone basis, what the market would bear for such items and what another party might charge for these items.
	The up-front arrangement consideration allocated to the Transferred Assets was recognized upon execution of the BioMarin Asset Purchase Agreement as the risks and rewards associated with the Transferred Assets transferred at that time. The Company used a discounted cash flow analysis to determine the value of the Transferred Assets. Key assumptions in the analysis included: the estimated market size for a compound targeted at Friedreich’s Ataxia, the estimated remaining costs of development and time to commercialization, and the probability of successfully developing and commercializing the program. Based on this analysis, the Company allocated $2,115,000 to the value of the Transferred Assets. However, as the recognized revenue is limited to the non-contingent consideration received, the Company recognized $2,000,000, the amount of the up-front payment, as revenue in the three months ended March 31, 2014.
	The estimated selling price of the Technology Transfer items was approximately $300,000 resulting in consideration allocation of approximately $11,000. However, as this item was not delivered prior to March 31, 2014, the Company did not recognize any revenue related to the Technology Transfer in the three months ended March 31, 2014. Repligen received the payment and recognized $125,675 of other revenues in September 2014 upon completion of the Technology Transfer.
	The Company believes that a change in the key assumptions used to determine best estimate of selling price for each of the deliverables would not have a significant effect on the allocation of arrangement consideration.
	In addition to the $2.1 million up-front payment, the Company is also eligible to receive up to $160 million in potential milestone payments from BioMarin comprised of:
		•	Up to $60 million related to the achievement of specified clinical and regulatory milestone events; and
		•	Up to $100 million related to the achievement of specified commercial sales events, specifically the first commercial sale in specific territories.
	The Company evaluated the potential milestones in accordance with ASC 605-28, which allows an entity to make an accounting policy election to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. This evaluation included an assessment of the risks that must be overcome to achieve the respective milestone as well as whether the achievement of the milestone was due in part to our initial clinical work, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.
	The Company believes that the $60 million of specified clinical and regulatory milestone payments are substantive. Therefore, any such milestones achieved will be recognized as revenue when earned.
	Any milestones achieved upon specified commercial sales events or future royalty payments are considered contingent revenue under the BioMarin Asset Purchase Agreement, and will be recognized as revenue when they are earned as there are no undelivered elements remaining and no continuing performance obligations under the arrangement.
	Therapeutics Licensing Agreements
	Activities under licensing agreements are evaluated in accordance with ASC 605-25 to determine if they represent a multiple element revenue arrangement. The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. The Company accounts for those components as separate units of accounting if the following two criteria are met:
		•	The delivered item or items have value to the customer on a stand-alone basis.
		•	If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within our control.
	Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables. If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative selling price. Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met.
	Future milestone payments, if any, under a license agreement will be recognized under the provisions of ASC 605-28, which the Company adopted on January 1, 2011. The Company has elected to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is substantive if:
		•	It can only be achieved based in whole or in part on either (1) the Company’s performance or (2) on the occurrence of a specific outcome resulting from the Company’s performance;
		•	There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and
		•	It would result in additional payments being due to the entity.
	The commercial milestone payments and royalty payments received under license agreements, if any, will be recognized as revenue when they are earned.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2015
Accumulated Other Comprehensive Income	4	Accumulated Other Comprehensive Income
	The following table summarizes the changes in accumulated other comprehensive income by component:
	(In thousands)		Unrealized gain			Foreign currency			Total
			(loss) on			translation gain
			investments			(loss)
	Balance at December 31, 2014		$	(33,054	)	$	(5,740,088	)	$	(5,773,142	)
	Other comprehensive income/(loss) before reclassifications			(17,369	)		(3,848,609	)		(3,865,978	)
	Amounts reclassified from accumulated other comprehensive income			—			—			—
	Net current period other comprehensive income/(loss)			(17,369	)		(3,848,609	)		(3,865,978	)
	Balance at March 31, 2015		$	(50,423	)	$	(9,588,697	)	$	(9,639,120	)

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share	5	Earnings Per Share
	The Company reports earnings per share in accordance with Accounting Standards Codification Topic 260, “Earnings Per Share,” which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents then outstanding. Potential common share equivalents consist of restricted stock awards and the incremental common shares issuable upon the exercise of stock options. Under the treasury stock method, unexercised “in-the-money” stock options and warrants are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period. Share-based payment awards that entitle their holders to receive non-forfeitable dividends before vesting are considered participating securities and are considered in the calculation of basic and diluted earnings per share.
	Basic and diluted weighted average shares outstanding were as follows:
			Three Months Ended
			March 31,
			2015		2014
	Weighted average common shares			32,754,862		31,962,843
	Dilutive common stock options			695,749		868,176
	Weighted average common shares, assuming dilution			33,450,611		32,831,019
	At March 31, 2015, there were outstanding options to purchase 1,295,312 shares of the Company’s common stock at a weighted average exercise price of $9.44 per share. For the three-month period ended March 31, 2015, 199,580 options to purchase shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive.
	At March 31, 2014, there were outstanding options to purchase 1,675,077 shares of the Company’s common stock at a weighted average exercise price of $5.78 per share. For the three-month period ended March 31, 2014, 207,431 options to purchase shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Stock-Based Compensation	6	Stock-Based Compensation
	For the three months ended March 31, 2015 and 2014, the Company recorded stock-based compensation expense of $701,982 and $307,425, respectively, for share-based awards granted under the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the “2001 Plan”) and the Repligen Corporation Amended and Restated 2012 Stock Option and Incentive Plan (the “2012 Plan,” and collectively with the 2001 Plan and the 1992 Repligen Corporation Stock Option Plan, the “Plans”).
	The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (loss):
			Three Months Ended
			March 31,
			2015			2014
	Cost of product revenue		$	42,907		$	26,562
	Research and development			69,271			31,603
	Selling, general and administrative			589,804			249,260
	Total		$	701,982		$	307,425
	The 2012 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock and other equity awards. Incentive options granted to employees under the Plans generally vest over a three to five-year period, with 20%-33% vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to non-employee directors under the Plans generally vest over one year. Options granted under the Plans have a maximum term of ten years from the date of grant and generally, the exercise price of the stock options equals the fair market value of the Company’s common stock on the date of grant. At March 31, 2015, options to purchase 1,295,312 shares were outstanding under the Plans. At March 31, 2015, 2,559,395 shares were available for future grant under the 2012 Plan.
	The Company uses the Black-Scholes option pricing model to calculate the fair value of share-based awards on the grant date. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award, and recognizes awards with service based vesting as expense over the employee’s requisite service period on a straight-line basis. The Company records the expense for share-based awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates whether the achievement of a performance-based milestone is probable as of the reporting date. The Company has no awards that are subject to market conditions. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures.
	Information regarding option activity for the three months ended March 31, 2015 under the Plans is summarized below:
			Options			Weighted-		Weighted-		Aggregate
			Outstanding			Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price Per		Contractual
						Share		Term
								(in years)
	Options outstanding at January 1, 2015			1,225,117		$	8.31
	Granted			182,921			14.26
	Exercised			(77,126	)		5.21
	Forfeited/Cancelled			(35,600	)		4.6
	Options outstanding at March 31, 2015			1,295,312		$	9.44		7.43	$	27,100,059
	Options exercisable at March 31, 2015			439,527		$	5.08		4.89	$	11,108,899
	Vested and expected to vest at March 31, 2015 (1)			771,366		$	11.9		8.8	$	14,239,180
	-1	This represents the number of vested options as of March 31, 2015 plus the number of unvested options expected to vest as of March 31, 2015 based on the unvested outstanding options at March 31, 2015 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.
	The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on March 31, 2015 of $30.36 and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on March 31, 2015.
	The weighted average grant date fair value of options granted during the three months ended March 31, 2015 and 2014 was $19.67 and $10.58, respectively. The total fair value of stock options that vested during the three months ended March 31, 2015 and 2014 was approximately $670,922 and $343,667, respectively.
	As of March 31, 2015, there was $7,067,939 of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 3.21 years. The Company expects 771,366 unvested options to vest over the next five years.

Cash_Cash_Equivalents_and_Mark

Cash, Cash Equivalents and Marketable Securities	3 Months Ended
	Mar. 31, 2015
Cash, Cash Equivalents and Marketable Securities	7	Cash, Cash Equivalents and Marketable Securities
	At March 31, 2015 and December 31, 2014, the Company’s investments included money market funds as well as short-term and long-term marketable securities. These marketable securities are classified as available-for-sale. Marketable securities are investments with original maturities of greater than 90 days. Long-term marketable securities are securities with maturities of greater than one year. The average remaining contractual maturity of marketable securities at March 31, 2015 is approximately 6.24 months.
	Management reviewed the Company’s investments as of March 31, 2015 and December 31, 2014 and concluded that there are no securities with other than temporary impairments in the investment portfolio. The Company does not intend to sell any investments in an unrealized loss position and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases.
	Investments in money market funds and marketable securities consisted of the following at March 31, 2015:
			March 31, 2015
			Amortized		Gross		Gross			Fair Value
			Cost		Unrealized		Unrealized
					Gain		Loss
	Marketable securities:
	U.S. Government and agency securities		$	13,904,520	$	4,221	$	(655	)	$	13,908,086
	Corporate and other debt securities			9,346,895		3,515		(766	)		9,349,644
				23,251,415		7,736		(1,421	)		23,257,730
	Long-term marketable securities:
	U.S. Government and agency securities			—		—		—			—
	Corporate and other debt securities			1,813,845		694		(181	)		1,814,358
				1,813,845		694		(181	)		1,814,358
	Total		$	25,065,260	$	8,430	$	(1,602	)	$	25,072,088
	At March 31, 2015, the Company’s investments included eighteen securities in unrealized loss positions with a total unrealized loss of approximately $2,000 and a total fair market value of approximately $7,246,000. All investments with gross unrealized losses have been in unrealized loss positions for less than 12 months. The unrealized losses were caused primarily by current economic and market conditions. There was no change in the credit risk of the securities. There were no realized gains or losses on the investments for the three months ended March 31, 2015 or the three months ended March 31, 2014.
	Investments in money market funds and marketable securities consisted of the following at December 31, 2014:
			December 31, 2014
			Amortized		Gross		Gross			Fair Value
			Cost		Unrealized		Unrealized
					Gain		Loss
	Marketable securities:
	U.S. Government and agency securities		$	12,716,167	$	2,174	$	(2,072	)	$	12,716,269
	Corporate and other debt securities			10,373,332		4,229		(3,621	)		10,373,940
				23,089,499		6,403		(5,693	)		23,090,209
	Long-term marketable securities:
	U.S. Government and agency securities			1,227,843		—		(207	)		1,227,636
	Corporate and other debt securities			2,326,066		—		(3,492	)		2,322,574
				3,553,909		—		(3,699	)		3,550,210
	Total		$	26,643,408	$	6,403	$	(9,392	)	$	26,640,419
	The contractual maturities of money market funds and marketable securities at March 31, 2015 were as follows:
			Amortized		Fair Value
			Cost
	Due in 1 year or less		$	23,251,415	$	23,257,730
	Due in 1 to 2 years			1,813,845		1,814,358
			$	25,065,260	$	25,072,088

Fair_Value_Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2015
Fair Value Measurement	8	Fair Value Measurement
	In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:
	Level 1		–		Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
	Level 2		–		Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly
	Level 3		–		Valuations based on inputs that are unobservable and significant to the overall fair value measurement
	The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.
	The Company’s fixed income investments are comprised of obligations of U.S. government agencies and corporate marketable securities. These investments have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. At least annually, the Company validates the prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. The Company did not adjust or override any fair value measurements provided by the pricing services as of March 31, 2015.
	The following fair value hierarchy table presents information about each major category of the Company’s assets measured at fair value on a recurring basis as of March 31, 2015:
			Fair value measurement at reporting date using:
			Quoted prices in			Significant		Significant		Total
			active markets for			other observable		unobservable
			identical assets			inputs		inputs
			(Level 1)			(Level 2)		(Level 3)
	Assets:
	Money market funds		$	3,890,976		$	—	$	—	$	3,890,976
	U.S. Government and agency securities			7,243,200			6,664,886		—		13,908,086
	Corporate and other debt securities			—			11,164,002		—		11,164,002
	Total		$	11,134,176		$	17,828,888	$	—	$	28,963,064
	The Company has no other assets or liabilities for which fair value measurement is either required or has been elected to be applied, other than the liabilities for contingent consideration recorded in connection with the Novozymes, BioFlash Partners, LLC (“BioFlash”) and Refine business combinations. The contingent consideration related to Novozymes is based upon actual amounts remaining to be paid to Novozymes Biopharma DK A/S, a company organized under the laws of Denmark (“Novozymes Denmark”) per the Deed of Settlement and Amendment entered into on May 5, 2014. The contingent consideration related to BioFlash is valued using management’s estimates of royalties to be paid to the former shareholders of BioFlash based on sales of the acquired assets. The contingent consideration related to the Refine Acquisition is valued using management’s estimates of expected future milestone payments based on forecasted sales and a portion of any receipts that might be received in connection with the resolution, withdrawal or settlement of certain patent disputes with a third party to be paid Refine. These valuations are Level 3 valuations as the primary inputs are unobservable.
	Changes in the fair value of contingent consideration in the three-month period ended March 31, 2015 are primarily attributable to an increase to the expected Refine milestone payment of $1,104,000, a $1,000,000 milestone payment to Refine and a $110,000 minimum royalty payment made to BioFlash, which were previously accrued. The following table provides a roll forward of the fair value of the contingent consideration:
	Balance at December 31, 2014		$	3,844,574
	Payments			(1,110,000	)
	Changes in fair value			1,109,670
	Balance at March 31, 2015		$	3,844,244
	The following tables provide quantitative information associated with the fair value measurement of the Company’s contingent consideration related to Refine using Level 3 inputs:
			Contingent Consideration
			Refine
	Fair value as of March 31, 2015		$3,425,000
	Valuation technique		Probability-adjusted
			discounted cash flow
	Remaining periods in which milestones can be achieved		2015 – 2016
			Fixed			Maximum		Accrued
			Earn-out			Variable		Balance
						Earn-out
	2015			3,500,000			850,000		3,322,000
	2016			4,250,000			1,250,000		103,000
	The significant unobservable inputs used in the fair value measurement of Refine’s contingent consideration are (i) the probabilities of a successful achievement of 2015 and 2016 sales milestones, (ii) the period in which these milestones are expected to be achieved and (iii) a discount rate. During the first quarter of 2015 the estimated fair value of the 2015 contingent payment was increased by $1,103,000 to $3,322,000 based upon a revised sales forecast for 2015. Increases or decreases in our projected sales during these periods may result in a significantly higher or lower fair value measurement, respectively and could result in a reversal of the current accrual.
	There were no remeasurements to fair value during the three months ended March 31, 2015 of financial assets and liabilities that are not measured at fair value on a recurring basis.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventories	9	Inventories
	Inventories relate to the Company’s bioprocessing business. The Company values inventory at cost or, if lower, market value, using the first-in, first-out method. The Company reviews its inventories at least quarterly and records a provision for excess and obsolete inventory based on its estimates of expected sales volume, production capacity and expiration dates of raw materials, work-in-process and finished products. Expected sales volumes are determined based on supply forecasts provided by key customers for the next 3 to 12 months. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements to cost of product revenue. Manufacturing of bioprocessing finished goods is done to order and tested for quality specifications prior to shipment. Reserves for excess and obsolete inventory were approximately $78,000 at March 31, 2015 and $78,000 at December 31, 2014.
	A change in the estimated timing or amount of demand for the Company’s products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. During all periods presented in the accompanying financial statements, there have been no material adjustments related to a revised estimate of inventory valuations.
	Work-in-process and finished products inventories consist of material, labor, outside processing costs and manufacturing overhead. Inventories consist of the following:
			March 31,		December 31,
			2015		2014
	Raw materials		$	5,706,085	$	5,373,860
	Work-in-process			2,203,158		2,256,265
	Finished products			4,326,476		4,753,508
	Total		$	12,235,719	$	12,383,633

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2015
Accrued Liabilities	10	Accrued Liabilities
	The Company estimates accrued liabilities by identifying services performed on the Company’s behalf, estimating the level of service performed and determining the associated cost incurred for such service as of each balance sheet date. For example, the Company would accrue for professional and consulting fees incurred with law firms, audit and accounting service providers and other third party consultants. These expenses are determined by either requesting those service providers to estimate unbilled services at each reporting date for services incurred or tracking costs incurred by service providers under fixed fee arrangements.
	The Company has processes in place to estimate the appropriate amounts to record for accrued liabilities, which principally involve the applicable personnel reviewing the services provided. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under or over-estimates the level of services performed or the costs of such services, the reported expenses for that period may be too low or too high. The date on which certain services commence, the level of services performed on or before a given date, and the cost of such services often require the exercise of judgment. The Company makes these judgments based upon the facts and circumstances known at the date of the financial statements.
	Accrued liabilities consist of the following:
			March 31, 2015		December 31, 2014
	Employee compensation		$	2,678,121	$	3,758,511
	Taxes			752,905		571,080
	Royalty and license fees			882,507		—
	Current portion of contingent consideration			3,478,358		1,135,061
	Professional fees			508,220		511,588
	Unearned revenue			216,751		129,904
	Other accrued expenses			535,582		712,919
	Total		$	9,052,444	$	6,819,063

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies	11	Commitments and Contingencies
	In March 2014, the Company entered into an amendment of its existing lease to expand the rented space from 55,694 to 75,594 square feet at 41 Seyon Street, Waltham, Massachusetts. Pursuant to the terms of the amended lease, Repligen will lease an additional 19,900 square feet (the “Expansion Space”) for a period of eight years and one month, commencing on August 1, 2014. The Expansion Space is a part of Repligen’s corporate headquarters.
	The amended lease provides for additional rent expense of approximately $361,000 on an annualized basis. Future minimum rental commitments under the amended lease as of March 31, 2015 are approximately $1,028,000 and $1,371,000 for the remainder of the year ending December 31, 2015, and the years ending December 2016, 2017, 2018 and 2019, respectively.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Taxes	12	Income Taxes
	For the three months ended March 31, 2015, the Company had income before taxes of approximately $4,198,000 and recorded a tax provision of approximately $1,269,000 for an effective tax rate of approximately 30.2%. For the three months ended March 31, 2014, the Company had income before taxes of approximately $5,398,000 and recorded a tax provision of $1,121,000 for an effective tax rate of approximately 20.8%. This was based on expected effective tax rates of 25.9% and 20.9% for the years ending December 31, 2015 and 2014, respectively. The effective income tax rate is based upon the forecasted income by jurisdiction. The effective tax rate differs from the U.S. statutory tax rate primarily due to the lower statutory tax rate in Sweden.
	The Company has net operating loss carryforwards of approximately $43,387,000 and business tax credits carryforwards of approximately $1,782,000 available to reduce future federal income taxes, if any. The net operating loss and business tax credits carryforwards will continue to expire at various dates through December 2032. Net operating loss carryforwards and available tax credits are subject to review and possible adjustment by the Internal Revenue Service and may be limited in the event of certain changes in the ownership interest of significant stockholders.
	As of December 31, 2014, we concluded that realization of deferred tax assets beyond December 31, 2014 is not more likely than not, and as such, as of December 31, 2014 we maintained a valuation allowance against the majority of our remaining deferred tax assets. As of March 31, 2015, we concluded that realization of deferred tax assets beyond March 31, 2015 is not more likely than not, and as such, as of March 31, 2015 we maintained a valuation allowance against the majority of our remaining deferred tax assets.
	The fiscal years ended March 31, 2007 through March 31, 2011 as well as the nine-month fiscal year ended December 31, 2011 and the years ended December 31, 2012, 2013 and 2014 are subject to examination by the Commonwealth of Massachusetts (“the Commonwealth”) taxing authorities. Currently, a corporate excise tax audit is underway in the Commonwealth for the fiscal years ended March 31, 2008 through 2011, and the nine-month period ended December 31, 2011. Fiscal years ended December 31, 2012, 2013 and 2014 are subject to examination by other states, U.S. federal and Sweden taxing authorities.

Segment_Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2015
Segment Reporting	13	Segment Reporting
	The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment. As a result, the financial information disclosed herein represents all of the material financial information related to the Company’s principal operating segment.
	The following table represents the Company’s total revenue by geographic area (based on the location of the customer):
			Three months ended
			March 31,
			2015			2014
	United States			28	%		49	%
	Sweden			38	%		32	%
	United Kingdom			19	%		18	%
	Other			15	%		1	%
				100	%		100	%
	Revenue from significant customers as a percentage of the Company’s total revenue is as follows:
			Three months ended
			March 31,
			2015			2014
	Upfront payment from sale of intellectual property to BioMarin			—			12	%
	GE Healthcare			37	%		40	%
	Bioprocessing Customer B			23	%		22	%
	Bioprocessing Customer C			16	%		14	%
	Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable and royalties and other receivables balances are as follows:
			March 31,			December 31,
			2015			2014
	GE Healthcare			43	%		29	%
	Bioprocessing Customer B			27	%		1	%

Acquisitions_Goodwill_and_Othe1

Acquisitions, Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Consideration Transferred	The total consideration transferred follows:
	Cash consideration,	$	21,169,660
	Value of common stock issued		4,000,000
	Estimated fair value of contingent consideration		1,370,000
	Total consideration transferred	$	26,539,660
Components and Allocation of Purchase Price	The components and allocation of the purchase price consists of the following amounts:
	Accounts receivable	$	1,646,746
	Inventory		1,034,657
	Other current assets		184,080
	Fixed assets		84,662
	Customer relationships		6,400,000
	Developed technology		2,000,000
	In process research and development (“IPR&D”)		1,600,000
	Trademark and trade name		700,000
	Accounts payable and other liabilities assumed		(431,307	)
	Goodwill		13,320,822
	Net assets acquired	$	26,539,660
Unaudited Supplemental Pro Forma Information	The following table presents unaudited supplemental pro forma information as if the Refine Acquisition had occurred as of January 1, 2014.
		Three Months ended			Three Months ended
		March 31,			March 31,
		2015			2014
	Total revenue	$	20,816,000		$	18,242,000
Other Intangible Assets - Finite-Lived	Other intangible assets consisted of the following at March 31, 2015:
		Gross Carrying			Accumulated			Weighted
		Amount			Amortization			Average
								Useful Life
								(in years)
	Technology – developed	$	3,283,913		$	(803,409	)		12
	In process research and development		1,600,000			—			—
	Patents		240,000			(155,000	)		8
	Customer relationships		11,702,387			(2,684,683	)		9
	Trademark/ tradename		700,000			—			—
	Total other intangible assets	$	17,526,300		$	(3,643,092	)		10
	Other intangible assets consisted of the following at December 31, 2014:
		Gross Carrying			Accumulated			Weighted
		Amount			Amortization			Average
								Useful Life
								(in years)
	Technology – developed	$	3,337,658		$	(750,066	)		12
	In process research and development		1,600,000			—			—
	Patents		240,000			(147,500	)		8
	Customer relationships		12,202,219			(2,546,004	)		9
	Trademark/ tradename		700,000			—			—
	Total other intangible assets	$	18,079,877		$	(3,443,570	)		10
Schedule of Amortization Expense for Amortized Intangible Assets	In each of the next five years, the Company expects to record amortization expense of:
	Years Ending	Amortization Expense
	December 31, 2015 (nine months remaining)	$	1,250,000
	December 31, 2016		1,715,000
	December 31, 2017		1,715,000
	December 31, 2018		1,551,000
	December 31, 2019		1,536,000
	December 31, 2020		1,208,000

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2015
Changes in Accumulated Other Comprehensive Income	The following table summarizes the changes in accumulated other comprehensive income by component:
	(In thousands)	Unrealized gain			Foreign currency			Total
		(loss) on			translation gain
		investments			(loss)
	Balance at December 31, 2014	$	(33,054	)	$	(5,740,088	)	$	(5,773,142	)
	Other comprehensive income/(loss) before reclassifications		(17,369	)		(3,848,609	)		(3,865,978	)
	Amounts reclassified from accumulated other comprehensive income		—			—			—
	Net current period other comprehensive income/(loss)		(17,369	)		(3,848,609	)		(3,865,978	)
	Balance at March 31, 2015	$	(50,423	)	$	(9,588,697	)	$	(9,639,120	)

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Basic and Diluted Weighted Average Shares Outstanding	Basic and diluted weighted average shares outstanding were as follows:
		Three Months Ended
		March 31,
		2015		2014
	Weighted average common shares		32,754,862		31,962,843
	Dilutive common stock options		695,749		868,176
	Weighted average common shares, assuming dilution		33,450,611		32,831,019

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Stock-Based Compensation Expense	The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (loss):
			Three Months Ended
			March 31,
			2015			2014
	Cost of product revenue		$	42,907		$	26,562
	Research and development			69,271			31,603
	Selling, general and administrative			589,804			249,260
	Total		$	701,982		$	307,425
Summary of Option Activity	Information regarding option activity for the three months ended March 31, 2015 under the Plans is summarized below:
			Options			Weighted-		Weighted-		Aggregate
			Outstanding			Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price Per		Contractual
						Share		Term
								(in years)
	Options outstanding at January 1, 2015			1,225,117		$	8.31
	Granted			182,921			14.26
	Exercised			(77,126	)		5.21
	Forfeited/Cancelled			(35,600	)		4.6
	Options outstanding at March 31, 2015			1,295,312		$	9.44		7.43	$	27,100,059
	Options exercisable at March 31, 2015			439,527		$	5.08		4.89	$	11,108,899
	Vested and expected to vest at March 31, 2015 (1)			771,366		$	11.9		8.8	$	14,239,180
	-1	This represents the number of vested options as of March 31, 2015 plus the number of unvested options expected to vest as of March 31, 2015 based on the unvested outstanding options at March 31, 2015 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

Cash_Cash_Equivalents_and_Mark1

Cash, Cash Equivalents and Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2015
Investments in Money Market Funds and Marketable Securities	Investments in money market funds and marketable securities consisted of the following at March 31, 2015:
		March 31, 2015
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gain		Loss
	Marketable securities:
	U.S. Government and agency securities	$	13,904,520	$	4,221	$	(655	)	$	13,908,086
	Corporate and other debt securities		9,346,895		3,515		(766	)		9,349,644
			23,251,415		7,736		(1,421	)		23,257,730
	Long-term marketable securities:
	U.S. Government and agency securities		—		—		—			—
	Corporate and other debt securities		1,813,845		694		(181	)		1,814,358
			1,813,845		694		(181	)		1,814,358
	Total	$	25,065,260	$	8,430	$	(1,602	)	$	25,072,088
	Investments in money market funds and marketable securities consisted of the following at December 31, 2014:
		December 31, 2014
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gain		Loss
	Marketable securities:
	U.S. Government and agency securities	$	12,716,167	$	2,174	$	(2,072	)	$	12,716,269
	Corporate and other debt securities		10,373,332		4,229		(3,621	)		10,373,940
			23,089,499		6,403		(5,693	)		23,090,209
	Long-term marketable securities:
	U.S. Government and agency securities		1,227,843		—		(207	)		1,227,636
	Corporate and other debt securities		2,326,066		—		(3,492	)		2,322,574
			3,553,909		—		(3,699	)		3,550,210
	Total	$	26,643,408	$	6,403	$	(9,392	)	$	26,640,419
Contractual Maturities of Money Market Funds and Marketable Securities	The contractual maturities of money market funds and marketable securities at March 31, 2015 were as follows:
		Amortized		Fair Value
		Cost
	Due in 1 year or less	$	23,251,415	$	23,257,730
	Due in 1 to 2 years		1,813,845		1,814,358
		$	25,065,260	$	25,072,088

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2015
Assets Measured at Fair Value on Recurring Basis	The following fair value hierarchy table presents information about each major category of the Company’s assets measured at fair value on a recurring basis as of March 31, 2015:
		Fair value measurement at reporting date using:
		Quoted prices in			Significant		Significant		Total
		active markets for			other observable		unobservable
		identical assets			inputs		inputs
		(Level 1)			(Level 2)		(Level 3)
	Assets:
	Money market funds	$	3,890,976		$	—	$	—	$	3,890,976
	U.S. Government and agency securities		7,243,200			6,664,886		—		13,908,086
	Corporate and other debt securities		—			11,164,002		—		11,164,002
	Total	$	11,134,176		$	17,828,888	$	—	$	28,963,064
Quantitative Information Associated With Fair Value Measurement of Contingent Consideration	The following tables provide quantitative information associated with the fair value measurement of the Company’s contingent consideration related to Refine using Level 3 inputs:
		Contingent Consideration
		Refine
	Fair value as of March 31, 2015	$3,425,000
	Valuation technique	Probability-adjusted
		discounted cash flow
	Remaining periods in which milestones can be achieved	2015 – 2016
		Fixed			Maximum		Accrued
		Earn-out			Variable		Balance
					Earn-out
	2015		3,500,000			850,000		3,322,000
	2016		4,250,000			1,250,000		103,000
Roll Forward of Fair Value of Contingent Consideration	The following table provides a roll forward of the fair value of the contingent consideration:
	Balance at December 31, 2014	$	3,844,574
	Payments		(1,110,000	)
	Changes in fair value		1,109,670
	Balance at March 31, 2015	$	3,844,244

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Schedule of Inventories	Inventories consist of the following:
		March 31,		December 31,
		2015		2014
	Raw materials	$	5,706,085	$	5,373,860
	Work-in-process		2,203,158		2,256,265
	Finished products		4,326,476		4,753,508
	Total	$	12,235,719	$	12,383,633

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Schedule of Accrued Liabilities	Accrued liabilities consist of the following:
		March 31, 2015		December 31, 2014
	Employee compensation	$	2,678,121	$	3,758,511
	Taxes		752,905		571,080
	Royalty and license fees		882,507		—
	Current portion of contingent consideration		3,478,358		1,135,061
	Professional fees		508,220		511,588
	Unearned revenue		216,751		129,904
	Other accrued expenses		535,582		712,919
	Total	$	9,052,444	$	6,819,063

Segment_Reporting_Tables

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2015
Percentage of Revenue from Significant Customers	Revenue from significant customers as a percentage of the Company’s total revenue is as follows:
		Three months ended
		March 31,
		2015			2014
	Upfront payment from sale of intellectual property to BioMarin		—			12	%
	GE Healthcare		37	%		40	%
	Bioprocessing Customer B		23	%		22	%
	Bioprocessing Customer C		16	%		14	%
Total Revenue
Percentage by Geographic Area or Significant Customers	The following table represents the Company’s total revenue by geographic area (based on the location of the customer):
		Three months ended
		March 31,
		2015			2014
	United States		28	%		49	%
	Sweden		38	%		32	%
	United Kingdom		19	%		18	%
	Other		15	%		1	%
			100	%		100	%
Accounts Receivable
Percentage by Geographic Area or Significant Customers	Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable and royalties and other receivables balances are as follows:
		March 31,			December 31,
		2015			2014
	GE Healthcare		43	%		29	%
	Bioprocessing Customer B		27	%		1	%

Acquisitions_Goodwill_and_Othe2

Acquisitions, Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended	7 Months Ended
	Jun. 02, 2014	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2014
Business Acquisition [Line Items]
Business acquisition, upfront payment	$21,169,660
Business acquisition, common stock shares issued, par value		$0.01	$0.01	$0.01
Business acquisition, common stock shares issued, value	4,000,000
Business acquisition, estimated fair value of contingent consideration	1,370,000
Payment of contingent considerations		99,000
Business acquisition, fair value of the net assets acquired	26,539,660
Finite lived intangible asset, useful life		10 years	10 years
Amortization expense		401,000
Customer relationships
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	6,400,000
Finite lived intangible asset, useful life		9 years	9 years
Technology - developed
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	2,000,000
Finite lived intangible asset, useful life		12 years	12 years
Trademark / tradename
Business Acquisition [Line Items]
Fair value of acquired indefinite lived intangible assets	700,000
In process research and development ("IPR&D")
Business Acquisition [Line Items]
Fair value of acquired indefinite lived intangible assets	1,600,000
Refine Technology, LLC
Business Acquisition [Line Items]
Working capital adjustment on purchase price	66,277
Business acquisition, common stock shares issued	215,285
Business acquisition, common stock shares issued, par value	$0.01
Business acquisition, common stock shares issued, value	4,000,000
Business acquisition, fair value of the net assets acquired	26,539,660
Business acquisition, transaction costs	817,835
Goodwill expected deductible period for tax purposes		15 years
Business acquisition, revenue		2,582,000		6,793,000
Refine Technology, LLC | Milestone Payments
Business Acquisition [Line Items]
Business acquisition, maximum potential contingent payment	10,900,000	9,900,000
Business acquisition, estimated fair value of contingent consideration	1,370,000
Payment of contingent considerations		1,000,000
Refine Technology, LLC | Up Front Payment
Business Acquisition [Line Items]
Business acquisition, upfront payment	21,235,937
Refine Technology, LLC | Resolution, Withdrawal or Settlement of Certain Patent Disputes
Business Acquisition [Line Items]
Business acquisition, maximum potential contingent payment	7,500,000
Refine Technology, LLC | Transition Services Agreement
Business Acquisition [Line Items]
Business acquisition, other consideration transferred	774,000
Refine Technology, LLC | Customer relationships
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	6,400,000
Finite lived intangible asset, useful life	10 years
Refine Technology, LLC | Technology - developed
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	2,000,000
Finite lived intangible asset, useful life	15 years
Refine Technology, LLC | Trademark / tradename
Business Acquisition [Line Items]
Fair value of acquired indefinite lived intangible assets	700,000
Refine Technology, LLC | In process research and development ("IPR&D")
Business Acquisition [Line Items]
Fair value of acquired indefinite lived intangible assets	$1,600,000

Consideration_Transferred_Deta

Consideration Transferred (Detail) (USD $)	0 Months Ended
	Jun. 02, 2014	Jun. 02, 2014
Business Acquisition [Line Items]
Cash consideration,	$21,169,660
Value of common stock issued	4,000,000
Estimated fair value of contingent consideration		1,370,000
Total consideration transferred	$26,539,660

Components_and_Allocation_of_P

Components and Allocation of Purchase Price (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Jun. 02, 2014
Business Combination, Separately Recognized Transactions [Line Items]
Accounts receivable			$1,646,746
Inventory			1,034,657
Other current assets			184,080
Fixed assets			84,662
Accounts payable and other liabilities assumed			-431,307
Goodwill	14,314,822	14,184,835	13,320,822
Net assets acquired			26,539,660
In process research and development ("IPR&D")
Business Combination, Separately Recognized Transactions [Line Items]
Business combination, intangible assets			1,600,000
Trademark / tradename
Business Combination, Separately Recognized Transactions [Line Items]
Business combination, intangible assets			700,000
Customer relationships
Business Combination, Separately Recognized Transactions [Line Items]
Business combination, intangible assets			6,400,000
Technology - developed
Business Combination, Separately Recognized Transactions [Line Items]
Business combination, intangible assets			$2,000,000

Unaudited_Supplemental_Pro_For

Unaudited Supplemental Pro Forma Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Business Combination, Separately Recognized Transactions [Line Items]
Total revenue	$20,816,000	$18,242,000

Other_Intangible_Assets_Detail

Other Intangible Assets (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Intangible Assets [Line Items]
Gross Carrying Amount	$17,526,300	$18,079,877
Accumulated Amortization	-3,643,092	-3,443,570
Weighted Average Useful Life (in years)	10 years	10 years
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Amount	3,283,913	3,337,658
Accumulated Amortization	-803,409	-750,066
Weighted Average Useful Life (in years)	12 years	12 years
Patents
Intangible Assets [Line Items]
Gross Carrying Amount	240,000	240,000
Accumulated Amortization	-155,000	-147,500
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Amount	11,702,387	12,202,219
Accumulated Amortization	-2,684,683	-2,546,004
Weighted Average Useful Life (in years)	9 years	9 years
In process research and development ("IPR&D")
Intangible Assets [Line Items]
Gross Carrying Amount, indefinite lived intangible assets	1,600,000	1,600,000
Trademark / tradename
Intangible Assets [Line Items]
Gross Carrying Amount, indefinite lived intangible assets	$700,000	$700,000

Amortization_Expense_for_Amort

Amortization Expense for Amortized Intangible Assets (Detail) (USD $)	Mar. 31, 2015
Finite-Lived Intangible Assets [Line Items]
December 31, 2015 (nine months remaining)	$1,250,000
31-Dec-16	1,715,000
31-Dec-17	1,715,000
31-Dec-18	1,551,000
31-Dec-19	1,536,000
31-Dec-20	$1,208,000

Revenue_Recognition_Additional

Revenue Recognition - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014	Jan. 30, 2014	Dec. 31, 2014	Sep. 03, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue recognized	$2,115,000
Non-refundable up-front payment	2,000,000
Payment to be received upon signing of agreement	125,675
Revenue recognized under revenue recognition, up front payment		2,000,000
Royalty and other revenue		1,991,166
Technology Transfer
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue recognized		0
Estimated selling price	300,000
Consideration allocated to transaction	11,000
Royalty and other revenue			125,675
Clinical Development
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone Payment	60,000,000
Potential milestone payments to be received	60,000,000
Initial Commercial Sales
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Potential milestone payments to be received	100,000,000
BioMarin Pharmaceutical, Inc. | Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront payment received under purchase agreement				2,000,000
Potential milestone payments to be received	160,000,000
Provision for refund	0
Revenue recognized	0				2,100,000
BioMarin Pharmaceutical, Inc. | Clinical Development | Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage relate to clinical development from Milestone payment	37.00%
BioMarin Pharmaceutical, Inc. | Initial Commercial Sales | Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage relate to clinical development from Milestone payment	63.00%
BioMarin Pharmaceutical, Inc. | Technology Transfer Payments | Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone Payment						$125,675

Changes_in_Accumulated_Other_C

Changes in Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2014	($5,773,142)
Other comprehensive income/(loss) before reclassifications	-3,865,978
Amounts reclassified from accumulated other comprehensive income	0
Net current period other comprehensive income/(loss)	-3,865,978
Balance at March 31, 2015	-9,639,120
Accumulated Net Unrealized Investment Gain (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2014	-33,054
Other comprehensive income/(loss) before reclassifications	-17,369
Amounts reclassified from accumulated other comprehensive income	0
Net current period other comprehensive income/(loss)	-17,369
Balance at March 31, 2015	-50,423
Accumulated Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2014	-5,740,088
Other comprehensive income/(loss) before reclassifications	-3,848,609
Amounts reclassified from accumulated other comprehensive income	0
Net current period other comprehensive income/(loss)	-3,848,609
Balance at March 31, 2015	($9,588,697)

Basic_and_Diluted_Weighted_Ave

Basic and Diluted Weighted Average Shares Outstanding (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Weighted Average Number of Shares Outstanding [Line Items]
Weighted average common shares	32,754,862	31,962,843
Dilutive common stock options	695,749	868,176
Weighted average common shares, assuming dilution	33,450,611	32,831,019

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Earnings Per Share [Line Items]
Stock options, outstanding	1,295,312	1,675,077	1,225,117
Stock options, weighted average exercise price	$9.44	$5.78	$8.31
Common stock excluded from calculation of diluted earnings per share	199,580	207,431

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$701,982	$307,425
Stock options, outstanding	1,295,312	1,675,077		1,225,117
Number of shares available for future grant	2,559,395
Closing price of common stock	$30.36
Weighted average grant date fair value of share-based awards granted	$19.67	$10.58
Total fair value of stock options vested	670,922	343,667
Total unrecognized compensation cost	$7,067,939
Unrecognized compensation cost, weighted average remaining requisite service period	3 years 2 months 16 days
Number of unvested options	771,366
Employee Stock Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			3 years
Employee Stock Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			5 years
Incentive options, term			10 years
Employee Stock Option | First Anniversary of The Date of Grant | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting percentage			20.00%
Employee Stock Option | First Anniversary of The Date of Grant | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting percentage			33.00%
Non-Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			1 year
Unvested Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period	5 years

StockBased_Compensation_Expens

Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$701,982	$307,425
Cost of product revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	42,907	26,562
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	69,271	31,603
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$589,804	$249,260

Summary_of_Information_Regardi

Summary of Information Regarding Option Activity (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Options Outstanding
Options outstanding at January 1, 2015	1,225,117		1,675,077
Granted	182,921
Exercised	-77,126
Forfeited/Cancelled	-35,600
Options outstanding at March 31, 2015	1,295,312		1,675,077
Options exercisable at March 31, 2015	439,527
Vested and expected to vest at March 31, 2015	771,366	[1]
Weighted-Average Exercise Price Per Share
Options outstanding at January 1, 2015	$8.31		$5.78
Granted	$14.26
Exercised	$5.21
Forfeited/Cancelled	$4.60
Options outstanding at March 31, 2015	$9.44		$5.78
Options exercisable at March 31, 2015	$5.08
Vested and expected to vest at March 31, 2015	$11.90	[1]
Weighted-Average Remaining Contractual Term (in years)
Options outstanding at March 31, 2015	7 years 5 months 5 days
Options exercisable at March 31, 2015	4 years 10 months 21 days
Vested and expected to vest at March 31, 2015	8 years 9 months 18 days	[1]
Aggregate Intrinsic Value
Options outstanding at March 31, 2015	$27,100,059
Options exercisable at March 31, 2015	11,108,899
Vested and expected to vest at March 31, 2015	$14,239,180	[1]
[1]	This represents the number of vested options as of March 31, 2015 plus the number of unvested options expected to vest as of March 31, 2015 based on the unvested outstanding options at March 31, 2015 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

Summary_of_Information_Regardi1

Summary of Information Regarding Option Activity (Parenthetical) (Detail) (Employee Stock Option)	Mar. 31, 2015
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8.00%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3.00%

Cash_Cash_Equivalents_and_Mark2

Cash Cash Equivalents and Marketable Securities - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
	Investment
Cash, cash equivalents and marketable securities [Line Items]
Long-term marketable securities, minimum original maturity term	1 year
Marketable securities, average remaining contractual maturity period	6 months 7 days
Number of debt securities in unrealized loss positions	18
Debt securities in unrealized loss positions, total unrealized loss	$2,000
Debt securities in unrealized loss positions, total fair market value	7,246,000
Credit risk	0
Gain (loss) on investments	$0	$0
Minimum
Cash, cash equivalents and marketable securities [Line Items]
Marketable securities, minimum original maturity term	90 days

Investments_in_Money_Market_Fu

Investments in Money Market Funds and Marketable Securities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$25,065,260	$26,643,408
Gross Unrealized Gain	8,430	6,403
Gross Unrealized Loss	-1,602	-9,392
Fair Value	25,072,088	26,640,419
Marketable securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	23,251,415	23,089,499
Gross Unrealized Gain	7,736	6,403
Gross Unrealized Loss	-1,421	-5,693
Fair Value	23,257,730	23,090,209
Marketable securities | U.S. Government and agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	13,904,520	12,716,167
Gross Unrealized Gain	4,221	2,174
Gross Unrealized Loss	-655	-2,072
Fair Value	13,908,086	12,716,269
Marketable securities | Corporate and other debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	9,346,895	10,373,332
Gross Unrealized Gain	3,515	4,229
Gross Unrealized Loss	-766	-3,621
Fair Value	9,349,644	10,373,940
Long-term marketable securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,813,845	3,553,909
Gross Unrealized Gain	694
Gross Unrealized Loss	-181	-3,699
Fair Value	1,814,358	3,550,210
Long-term marketable securities | U.S. Government and agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,227,843
Gross Unrealized Loss		-207
Fair Value		1,227,636
Long-term marketable securities | Corporate and other debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,813,845	2,326,066
Gross Unrealized Gain	694
Gross Unrealized Loss	-181	-3,492
Fair Value	$1,814,358	$2,322,574

Contractual_Maturities_of_Mone

Contractual Maturities of Money Market Funds and Marketable Securities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Due in 1 year or less	$23,251,415
Due in 1 to 2 years	1,813,845
Amortized Cost	25,065,260	26,643,408
Due in 1 year or less	23,257,730
Due in 1 to 2 years	1,814,358
Fair Value	$25,072,088	$26,640,419

Major_Category_of_Assets_Measu

Major Category of Assets Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, USD $)	Mar. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	$28,963,064
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	3,890,976
U.S. Government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	13,908,086
Corporate and other debt securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	11,164,002
Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	11,134,176
Quoted prices in active markets for identical assets (Level 1) | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	3,890,976
Quoted prices in active markets for identical assets (Level 1) | U.S. Government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	7,243,200
Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	17,828,888
Significant other observable inputs (Level 2) | U.S. Government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	6,664,886
Significant other observable inputs (Level 2) | Corporate and other debt securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	$11,164,002

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 02, 2014	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of other assets	$0
Fair value of other liabilities	0
Increase to milestone payment	1,112,374	98,320
Accrued Balance			1,370,000
Payment of contingent considerations	99,000
Refine Technology, LLC
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Increase to milestone payment	1,104,000
Refine Technology, LLC | Milestone Payments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Accrued Balance			1,370,000
Payment of contingent considerations	1,000,000
Bio Flash | Minimum
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Royalty payment	110,000
Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Increase to milestone payment	1,103,000
Accrued Balance	3,425,000
Scenario, Forecast | Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Accrued Balance				$103,000	$3,322,000

Quantitative_Information_Assoc

Quantitative Information Associated With Fair Value Measurement of Contingent Consideration (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Jun. 02, 2014
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Accrued Balance				$1,370,000
Refine Technology, LLC | Milestone Payments
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Accrued Balance				1,370,000
Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Accrued Balance	3,425,000
Valuation technique	Probability-adjusted discounted cash flow
Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments | Minimum
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Remaining periods in which milestones can be achieved	2015
Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments | Maximum
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Remaining periods in which milestones can be achieved	2016
Significant unobservable inputs (Level 3) | Scenario, Forecast | Refine Technology, LLC | Milestone Payments
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fixed Earn-out		4,250,000	3,500,000
Maximum Variable Earn-out		1,250,000	850,000
Accrued Balance		$103,000	$3,322,000

Roll_Forward_of_Fair_Value_of_

Roll Forward of Fair Value of Contingent Consideration (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	$3,844,574
Payments	-1,110,000
Changes in fair value	1,109,670
Balance at March 31, 2015	$3,844,244

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Reserves for excess and obsolete inventory	$78,000	$78,000

Schedule_of_Inventories_Detail

Schedule of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$5,706,085	$5,373,860
Work-in-process	2,203,158	2,256,265
Finished products	4,326,476	4,753,508
Total	$12,235,719	$12,383,633

Schedule_of_Accrued_Liabilitie

Schedule of Accrued Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$2,678,121	$3,758,511
Taxes	752,905	571,080
Royalty and license fees	882,507
Current portion of contingent consideration	3,478,358	1,135,061
Professional fees	508,220	511,588
Unearned revenue	216,751	129,904
Other accrued expenses	535,582	712,919
Total	$9,052,444	$6,819,063

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended
	Mar. 31, 2014	Mar. 31, 2015
	sqft
Commitments and Contingencies [Line Items]
Lease agreement, term	8 years 1 month
Lease agreement, commencement date	1-Aug-14
Before Amendment
Commitments and Contingencies [Line Items]
Lease agreement, space	55,694
After Amendment
Commitments and Contingencies [Line Items]
Lease agreement, space	75,594
Future minimum rental commitment, reminder of 2015		$1,028,000
Future minimum rental commitment, 2016		1,371,000
Future minimum rental commitment, 2017		1,371,000
Future minimum rental commitment, 2018		1,371,000
Future minimum rental commitment, 2019		1,371,000
Expansion Space
Commitments and Contingencies [Line Items]
Lease agreement, space	19,900
Annual rent expense	361,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2015
Income Taxes [Line Items]
Income before income taxes	$4,198,473	$5,398,105
Income tax provision	1,268,986	1,121,002
Effective tax rate	30.20%	20.80%
Expected effective tax rate			20.90%
Scenario, Forecast
Income Taxes [Line Items]
Expected effective tax rate				25.90%
Maximum
Income Taxes [Line Items]
Net operating loss and business tax credit carry forwards expiration date	At various dates through December 2032.
Available to Reduce Future Federal Income Taxes
Income Taxes [Line Items]
Net operating loss carry forwards	43,387,000
Business tax credit carry forwards	$1,782,000

Segment_Reporting_Additional_I

Segment Reporting - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting Information [Line Items]
Number of operating segment	1

Percentage_of_Revenue_by_Geogr

Percentage of Revenue by Geographic Area (Detail) (Geographic Concentration Risk, Total Revenue)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Concentration Risk [Line Items]
Revenues, percentage by country	100.00%	100.00%
United States
Concentration Risk [Line Items]
Revenues, percentage by country	28.00%	49.00%
Sweden
Concentration Risk [Line Items]
Revenues, percentage by country	38.00%	32.00%
United Kingdom
Concentration Risk [Line Items]
Revenues, percentage by country	19.00%	18.00%
Other
Concentration Risk [Line Items]
Revenues, percentage by country	15.00%	1.00%

Percentage_of_Revenue_from_Sig

Percentage of Revenue from Significant Customers (Detail) (Customer Concentration Risk, Sales Revenue)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
BioMarin Pharmaceutical, Inc.
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue		12.00%
GE Healthcare
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue	37.00%	40.00%
Bioprocessing Customer B
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue	23.00%	22.00%
Bioprocessing Customer C
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue	16.00%	14.00%

Percentage_of_Accounts_Receiva

Percentage of Accounts Receivable by Significant Customers (Detail) (Customer Concentration Risk, Accounts Receivable)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
GE Healthcare
Concentration Risk [Line Items]
Accounts receivable, percentage by customer	43.00%	29.00%
Bioprocessing Customer B
Concentration Risk [Line Items]
Accounts receivable, percentage by customer	27.00%	1.00%